Nintedanib Newbury

Nintedanib, the active ingredient in Nintedanib Newbury, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nintedanib is used to target fibrotic and neoplastic processes in several lung‑related conditions.

- Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: helps preserve lung capacity and delay worsening. - Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth and angiogenesis.

Nintedanib may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools. - Nausea: feeling sick. - Decreased appetite: reduced desire to eat. - Abdominal pain: stomach discomfort.

Serious or Rare Side Effects: - Liver enzyme elevation: increased ALT/AST. - Bleeding events: gastrointestinal hemorrhage. - Interstitial lung disease worsening: rapid respiratory decline.

When prescribing Nintedanib, clinicians should consider several safety measures.

- Monitor liver function: perform baseline and periodic ALT/AST tests. - Assess bleeding risk: avoid concomitant anticoagulants if possible. - Evaluate cardiovascular status: watch for hypertension or thrombotic events. - Pregnancy and lactation: use only if benefits outweigh risks; limited data. - Renal impairment: adjust monitoring in severe kidney disease. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Nintedanib can interact with other medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin): heightened bleeding risk. - Antiplatelet agents (e.g., aspirin, clopidogrel): increased hemorrhage potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise levels. - P‑glycoprotein inhibitors (e.g., verapamil): could affect drug transport. - CYP3A4 inducers (e.g., rifampicin): may reduce efficacy.